Mast cells, basophils and mastocytosis

Clinical Immunology

Volumn , Issue , 2008, Pages 345-360

  Metz, Martin ^a   Brockow, Knut ^b   Metcalfe, Dean D ^c   Galli, Stephen J ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882826468     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-04404-2.10022-3     Document Type: Chapter

References (40)

1. Metcalfe D.D., Baram D., Mekori Y.A. Mast cells. Physiol Rev 1997, 77:1033-1079.
2. Galli S.J., Kalesnikoff J., Grimbaldeston M.A., et al. Mast cells as 'tunable' effector and immunoregulatory cells: recent advances. Annu Rev Immunol 2005, 23:749-786.
3. Galli S.J., Metcalfe D.D., Arber D., et al. Basophils and mast cells and their disorders. Williams hematology 2005, 879-897. McGraw-Hill Medical, New York. 7th edn. M.A. Lichtman, E. Beutler, T.J. Kipps (Eds.).
4. Kinet J.P. The high-affinity IgE receptor (Fc epsilon RI): from physiology to pathology. Annu Rev Immunol 1999, 17:931-972.
5. Inomata N., Tomita H., Ikezawa Z., et al. Differential gene expression profile between cord blood progenitor-derived and adult progenitor-derived human mast cells. Immunol Lett 2005, 98:265-271.
6. Costa J.J., Demetri G.D., Harrist T.J., et al. Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J Exp Med 1996, 183:2681-2686.
7. Marone G., Triggiani M., Genovese A., et al. Role of human mast cells and basophils in bronchial asthma. Adv Immunol 2005, 88:97-160.
8. Lantz C.S., Boesiger J., Song C.H., et al. Role for interleukin-3 in mast-cell and basophil development and in immunity to parasites. Nature 1998, 392:90-93.
9. Caughey G.H. New developments in the genetics and activation of mast cell proteases. Mol Immunol 2002, 38:1353-1357.
10. Hallgren J., Pejler G. Biology of mast cell tryptase. An inflammatory mediator. FEBS J 2006, 273:1871-1895.
11. Schwartz L.B. Effector cells of anaphylaxis: mast cells and basophils. Novartis Foundation Symp 2004, 2004:276-285.
12. Metz M., Piliponsky A.M., Chen C-C., et al. Mast cells can enhance resistance to snake and honeybee venoms. Science 2006, 313:526-530.
13. Boyce J.A. The role of mast cells in asthma. Prostaglandins Leukoc Essent Fatty Acids 2003, 69:195-205.
14. Marshall J.S. Mast-cell responses to pathogens. Nature Rev Immunol 2004, 4:787-799.
15. Paul W.E., Seder R.A., Plaut M. Lymphokine and cytokine production by Fc epsilon RI+ cells. Adv Immunol 1993, 53:1-29.
16. Grimbaldeston M.A., Metz M., Yu M., et al. Effector and potential immunoregulatory roles of mast cells in IgE-associated acquired immune responses. Curr Opin Immunol 2006, 18:751-760.
17. Zhu D., Kepley C.L., Zhang K., et al. A chimeric human-cat fusion protein blocks cat-induced allergy. Nature Med 2005, 11:446-449.
18. Iikura M., Yamaguchi M., Fujisawa T., et al. Secretory IgA induces degranulation of IL-3-primed basophils. J Immunol 1998, 161:1510-1515.
19. Sampson H.A., Munoz-Furlong A., Campbell R.L., et al. Second symposium on the definition and management of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006, 117:391-397.
20. Ali F.R., Oldfield W.L., Higashi N., et al. Late asthmatic reactions induced by inhalation of allergen-derived T cell peptides. Am J Respir Crit Care Med 2004, 169:20-26.
21. Rosbotham J.L., Malik N.M., Syrris P., et al. Lack of c-kit mutation in familial urticaria pigmentosa. Br J Dermatol 1999, 140:849-852.
22. Kettelhut B.V., Metcalfe D.D. Pediatric mastocytosis. J Invest Dermatol 1991, 96:15S-18S.
23. Valent P., Sperr W.R., Schwartz L.B., et al. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. J Allergy Clin Immunol 2004, 114:3-11.
24. Brockow K., Akin C., Huber M., et al. Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: relationship to symptomatology, tryptase levels, and bone marrow pathology. J Am Acad Dermatol 2003, 48:508-516.
25. Parker R.I. Hematologic aspects of systemic mastocytosis. Hematol Oncol Clin North Am 2000, 14:557-568.
26. Garriga M.M., Friedman M.M., Metcalfe D.D. A survey of the number and distribution of mast cells in the skin of patients with mast cell disorders. J Allergy Clin Immunol 1988, 82:425-432.
27. Oude Elberink J.N., de Monchy J.G., Kors J.W., et al. Fatal anaphylaxis after a yellow jacket sting, despite venom immunotherapy, in two patients with mastocytosis. J Allergy Clin Immunol 1997, 99:153-154.
28. Jensen R.T. Gastrointestinal abnormalities and involvement in systemic mastocytosis. Hematol Oncol Clin North Am 2000, 14:579-623.
29. Valent P., Horny H.P., Li C.Y., et al. Pathology and genetics of tumors of hematopoietic and lymphoid tissue. World Health Organization classification of tumors 2001, 293-302. IARC Press, Lyon. E. Jaffe, N. Harris, H. Stein, J. Vardiman (Eds.).
30. Caplan R.M. The natural course of urticaria pigmentosa. Analysis and follow-up of 112 cases. Arch Dermatol 1963, 87:146-157.
31. Brockow K., Scott L.M., Worobec A.S., et al. Regression of urticaria pigmentosa in adult patients with systemic mastocytosis: correlation with clinical patterns of disease. Arch Dermatol 2002, 138:785-790.
32. Akin C., Metcalfe D.D. The biology of Kit in disease and the application of pharmacogenetics. J Allergy Clin Immunol 2004, 114:13-19.
33. Pardanani A., Ketterling R.P., Brockman S.R., et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003, 102:3093-3096.
34. Schwartz L.B., Irani A.M. Serum tryptase and the laboratory diagnosis of systemic mastocytosis. Hematol Oncol Clin North Am 2000, 14:641-657.
35. Horny H.P., Valent P. Histopathological and immunohistochemical aspects of mastocytosis. Int Arch Allergy Immunol 2002, 127:115-117.
36. Escribano L., Orfao A., Diaz-Agustin B., et al. Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood 1998, 91:2731-2736.
37. Worobec A.S. Treatment of systemic mast cell disorders. Hematol Oncol Clin North Am 2000, 14:659-687.
38. Worobec A.S., Kirshenbaum A.S., Schwartz L.B., et al. Treatment of three patients with systemic mastocytosis with interferon alpha-2b. Leuk Lymphoma 1996, 22:501-508.
39. Kluin-Nelemans H.C., Oldhoff J.M., Van Doormaal J.J., et al. Cladribine therapy for systemic mastocytosis. Blood 2003, 102:4270-4276.
40. Akin C., Brockow K., D'Ambrosio C., et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol 2003, 31:686-692.